Seminars in Oncology
Volume 35, Issue 5 , Pages 507-521 , October 2008

Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience

  • George A. Omura

      Affiliations

    • Corresponding Author InformationAddress correspondence to George A. Omura, MD, FACP, 3621 Crestside Rd, Birmingham, AL 35223

References 

  1. Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin-combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol. 1991;41:230–233
  2. Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a GOG study. J Clin Oncol. 1995;13:2752–2756
  3. Hreshchyshyn MM, Park RC, Blessing JA, et al. The role of adjuvant therapy in stage I ovarian cancer (from the GOG). Am J Obstet Gynecol. 1980;138:139–145
  4. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990;322:1021–1027
  5. Buchsbaum HJ, Brady MF, Delgado G, et al. Surgical staging of ovarian carcinoma: a GOG study. Surg Gynecol Obstet. 1989;169:226–232
  6. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32p or cyclophosphamide-cisplatin: a GOG study. J Clin Oncol. 2003;21:4350–4355
  7. Trimbos JB, Parmar M, Vergote I, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105–112
  8. Bell J, Brady M, Young R, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage ovarian carcinoma: a GOG study. Gynecol Oncol. 2006;102:432–439
  9. Markman M, Blessing J, Rubin S, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a GOG study. Gynecol Oncol. 2006;101:436–440
  10. Brady LW, Blessing JA, Slayton RE, et al. Radiotherapy, chemotherapy and combined therapy in stage III epithelial ovarian cancer (for the GOG). Cancer Clin Trials. 1979;2:111–120
  11. Park RC, Blom J, DiSaia PJ, et al. Treatment for women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin (from the GOG). Cancer. 1980;45:2529–2542
  12. Gall S, Bundy B, Beecham J, et al. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan plus Corynebacterium parvum (a GOG study). Gynecol Oncol. 1986;25:26–36
  13. Omura GA, Morrow CP, Blessing JA, et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983;51:783–789
  14. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammine-platinum(II)(NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976;60:55–60
  15. Omura G, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a GOG study. Cancer. 1986;57:1725–1730
  16. Omura GA, Brady MF, Homesley HD, et al. Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the GOG experience. J Clin Oncol. 1991;9:1138–1150
  17. Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a GOG study. J Clin Oncol. 1989;7:457–465
  18. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol. 1991;9:1668–1674
  19. duBois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006;24:1127–1135
  20. Bookman MA. ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. [abstract] J Clin Oncol. 2006;24(Suppl):5002
  21. Creasman WT, Omura G, Brady MF, et al. A randomized study of cyclophosphamide, doxorubicin and cisplatin with or without BCG in patients with suboptimal stage III and IV ovarian cancer: a GOG study. Gynecol Oncol. 1990;39:239–243
  22. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose intense therapy in suboptimally debulked ovarian cancer: a GOG study. J Clin Oncol. 1995;13:1589–1599
  23. Grenman S, Wiklund T, Jalkanen J, et al. A randomized phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer. 2006;42:2196–2199
  24. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a GOG study. J Clin Oncol. 1994;12:1748–1753
  25. McGuire WP, Hoskins WJ, Brady MF, et al. A phase III randomized study of cyclophosphamide and cisplatin versus paclitaxel and cisplatin in patients with suboptimal stage III and IV epithelial ovarian cancer. N Engl J Med. 1996;334:1–6
  26. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708
  27. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a GOG study. J Clin Oncol. 2000;18:106–115
  28. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–515
  29. Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13(Suppl):144–148
  30. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–2666
  31. Omura GA, Brady MF, Look KY, et al. Phase III trial of a paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study (GOG, SWOG, NCCTG, ECOG). J Clin Oncol. 2003;21:2843–2848
  32. Spriggs D, Brady M, Vacarello L, et al. A phase III randomized trial of IV cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a GOG study. J Clin Oncol. 2007;25:4466–4471
  33. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian and peritoneal carcinoma: a phase I study of the GOG. J Clin Oncol. 1996;14:1895–1902
  34. Ozols R, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a GOG study. J Clin Oncol. 2003;21:3194–3200
  35. Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using explanatory analysis (GOG protocol 158). Gynecol Oncol. 2005;99:71–79
  36. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682–1691
  37. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036–1045
  38. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a GOG study. J Clin Oncol. 2007;25:5165–5171
  39. Alberts D, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  40. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the GOG, SWOG, and ECOG. J Clin Oncol. 2001;19:1001–1007
  41. Armstrong DK, Bundy BN, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43
  42. Walker JL, Armstrong D, Huang H, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a GOG study. Gynecol Oncol. 2006;100:27–32
  43. Wenzel L, Huang H, Armstrong D, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a GOG study. J Clin Oncol. 2007;25:437–443
  44. Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 2006;354:1641–1643
  45. Varia M, Stehman FB, Bundy B, et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the GOG. J Clin Oncol. 2003;21:2849–2855
  46. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460–2465
  47. Rose PG, Nerenstone S, Brady M, et al. Secondary surgical cytoreduction in advanced ovarian carcinoma: a GOG study. N Engl J Med. 2004;351:2489–2497
  48. Wenzel L, Huang H, Monk B, et al. Quality of life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a GOG study. J Clin Oncol. 2005;23:5605–5612
  49. Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a GOG study (a final report). Cancer. 1985;56:243–248
  50. Williams S, Blessing JA, Moore DH, et al. Cisplatin, vinblastine, and bleomycin in recurrent ovarian germ cell tumors: a trial of the GOG. Ann Intern Med. 1989;3:22–27
  51. Williams SD, Blessing JA, Hatch KD, et al. Chemotherapy of advanced dysgerminoma: trials of the GOG. J Clin Oncol. 1991;9:1950–1955
  52. Williams SD, Blessing JA, DiSaia PJ, et al. Second-look laparotomy in ovarian germ cell tumors: the GOG experience. Gynecol Oncol. 1994;52:287–291
  53. Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a GOG study. Gynecol Oncol. 1999;72:131–137
  54. Morrow CP, Bundy BN, Hoffman J, et al. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary (A GOG study). Am J Clin Oncol CCT. 1986;9:24–26
  55. Thigpen JT, Blessing JA, DeGeest K, et al. Cisplatin as initial therapy in ovarian carcinosarcomas: a GOG study. Gynecol Oncol. 2004;93:336–339
  56. Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: 1 (Clinical-pathologic findings of a prospective study). Obstet Gynecol. 1984;63:825–832
  57. Creasman WT, DeGeest K, DiSaia PJ, et al. Significance of true surgical pathologic staging: a GOG study. Am J Obstet Gynecol. 1999;181:31–34
  58. Morrow CP, Bundy B, Kurman R, et al. Relationship between surgical-pathological risk factors and outcome in clinical stages I and II carcinoma of the endometrium (a GOG study). Gynecol Oncol. 1991;40:55–65
  59. Homesley HD, Boike G, Spiegel GW. Feasibility of laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a GOG study. Int J Gynecol Cancer. 2004;14:341–347
  60. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic irradiation therapy in intermediate risk endometrial adenocarcinoma: a GOG study. Gynecol Oncol. 2004;92:744–751
  61. Randall M, Filiaci V, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a GOG study. J Clin Oncol. 2006;24:36–44
  62. Thigpen JT, Brady MF, Homesley H, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a GOG study. J Clin Oncol. 2004;22:3902–3908
  63. Bruner DW, Barsevick A, Tian C, et al. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a GOG study. Qual Life Res. 207;16:89-100.
  64. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer. 2006;95:266–271
  65. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the GOG. J Clin Oncol. 1999;17:1736–1744
  66. Whitney CW, Brunetto VL, Zaino R, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a GOG study. Gynecol Oncol. 2004;92:4–9
  67. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a GOG study. Gynecol Oncol. 2004;92:10–14
  68. Cohen CJ, Bruckner HW, Deppe G, et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: a GOG study. Obstet Gynecol. 1984;63:719–726
  69. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a GOG study. J Clin Oncol. 1994;12:1408–1414
  70. Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a GOG study. Gynecol Oncol. 1990;36:166–171
  71. Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3808–3813
  72. Fleming GF, Filiaci VL, Bentley R, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-hour paclitaxel + filgrastim in endometrial carcinoma: a GOG study. Ann Oncol. 2004;15:1173–1178
  73. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a GOG study. J Clin Oncol. 2004;22:2159–2166
  74. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a GOG study. Cancer. 1993;71:1702–1709
  75. Omura GA, Major FJ, Blessing JA, et al. A randomized study of Adriamycin with and without dimethyl triazenimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–632
  76. Omura GA, Major FJ, Lifshitz S, et al. A randomized clinical trial of adjuvant Adriamyin in uterine sarcomas: a GOG study. J Clin Oncol. 1985;3:1240–1245
  77. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for locally resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–1654
  78. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986;12:2127–2130
  79. Muss HB, Bundy BN, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the GOG). Cancer. 1985;55:1648–1653
  80. Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinoma of the uterus: a GOG study. Gynecol Oncol. 2000;79:147–153
  81. Homesley HD, Filiaci VL, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine sarcoma: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:526–531
  82. Wolfson AE, Brady MF, Mannel RS, et al. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation versus cisplatin-ifosfamide+mesma in optimally debulked stage I-IV carcinosarcoma of the uterus. Gynecol Oncol. 2007;107:177–185
  83. Curry SL, Schlaerth JB, Kohorn EI, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole. Am J Obstet Gynecol. 1989;160:805–811
  84. Curry SL, Blessing JA, DiSaia PJ, et al. A prospective randomized comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine in “poor prognosis” metastatic gestational trophoblastic disease (a GOG study). Obstet Gynecol. 1989;73:357–362
  85. Delgado G, Bundy BN, Fowler WC, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a GOG study. Gynecol Oncol. 1989;35:314–320
  86. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a GOG study. Gynecol Oncol. 1990;38:352–357
  87. Keys H, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical cancer: a randomized trial of the GOG. Gynecol Oncol. 2003;89:343–353
  88. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a GOG study. Gynecol Oncol. 1999;73:177–183
  89. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: followup of a GOG study. Int J Radiat Oncol Biol Phys. 2006;65:169–176
  90. Hreshchyshyn MM, Aron BS, Boronow RC, et al. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys. 1979;5:317–322
  91. Symonds RP, Collingwood M, Kirwan J, et al. Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systemic review. Cancer Treat Rev. 2004;30:405–414
  92. Stehman F, Bundy BN, Keys H, et al. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix: a GOG study. Am J Obstet Gynecol. 1988;159:87–94
  93. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–1348
  94. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613
  95. Keys HM, Bundy BN, Stehman FB, et al. Weekly cisplatin chemotherapy during irradiation improves survival and reduces relapses for patients with bulky stage IB cervical cancer treated with irradiation and adjuvant hysterectomy: results of a randomized GOG trial. N Engl J Med. 1999;340:1154–1161
  96. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143
  97. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemoradiation for locally advanced cervical cancer: results of a randomized GOG study. N Engl J Med. 1999;340:1144–1153
  98. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966–972
  99. Lanciano R, Calkins A, Bundy B, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a GOG study. J Clin Oncol. 2005;23:8289–8295
  100. Wallace HJ, Hreshchyshyn MM, Wilbanks GD, et al. Comparison of the therapeutic effects of Adriamycin alone versus Adriamycin plus vincristine versus Adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep. 1978;62:1434–1441
  101. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix (a GOG study). J Clin Oncol. 1985;3:1079–1085
  102. Thigpen JT, Blessing JA, DiSaia , et al. A randomized comparison of a rapid versus prolonged (24 hour) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a GOG study. Gynecol Oncol. 1989;32:198–202
  103. McGuire WP, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a GOG study. J Clin Oncol. 1989;7:1462–1468
  104. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: a GOG study. J Clin Oncol. 1997;15:165–171
  105. Bloss J, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a GOG study. J Clin Oncol. 2002;20:1832–1837
  106. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a GOG study. J Clin Oncol. 2004;22:3113–3119
  107. McQuellon RP, Thaler H, Cella D, et al. Quality of life outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel for women with metastatic cervix cancer: results from the GOG study #169. Gynecol Oncol. 2006;101:296–304
  108. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a GOG study. J Clin Oncol. 2005;23:4626–4633
  109. Monk BJ, Huang H, Cella D, et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a GOG study. J Clin Oncol. 2005;23:4617–4625
  110. Homesley HD, Bundy BN, Sedlis A, et al. A randomized study of radiation therapy versus pelvic node resection for patients with invasive squamous cell carcinoma of the vulva having positive groin nodes (a GOG study). Obstet Gynecol. 1986;68:733–740
  111. Schilder R, Sill M, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a GOG study. Clin Cancer Res. 2005;11:5539–5548
  112. Smith S, Richards WE, Caito K, et al. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a GOG study. Gynecol Oncol. 2001;83:586–592
  113. Reedy M, Gallion H, Fowler J, et al. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a GOG study. Gynecol Oncol. 2002;85:255–259
  114. Baysal B, DeLoia J, Willett-Brozick J, et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol. 2004;95:62–69
  115. Wilcox CB, Baysal BE, Gallion HH, et al. High resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005;159:114–122
  116. Havrilesky L, Darcy KM, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a GOG study. J Clin Oncol. 2003;21:3814–3825
  117. He X, Ee PLR, Coon J, et al. Alternative splicing of the mutlidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20(1). Clin Cancer Res. 2004;10:4652–4660
  118. Burger RA, Darcy KM, DiSaia PJ, et al. Association between serum levels of soluble tumor necrosis factor receptors/CA125 and disease progression in patients with epithelial ovarian malignancy: a GOG study. Cancer. 2004;101:106–115
  119. Barakat R, Bundy B, Spirtos N, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in women with stage I or II endometrial cancer: a GOG study. J Clin Oncol. 2006;24:587–592
  120. Trimble C, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a GOG study. Cancer. 2006;106:812–819
  121. Zaino R, Kauderer J, Trimble C, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a GOG study. Cancer. 2006;106:804–811

 This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and the GOG Statistical Office (CA 37517).

 Address reprint requests to Denise Mackey, Gynecologic Oncology Group, Suite 1020, Four Penn Center, 1600 JFK Blvd, Philadelphia, PA 19102.

PII: S0093-7754(08)00171-1

doi: 10.1053/j.seminoncol.2008.07.007

Seminars in Oncology
Volume 35, Issue 5 , Pages 507-521 , October 2008

Article Tools